Lung Transplant for Refractory Lung-Limited Stage IV Non-Small Cell Lung Cancer

Area of Science:

• Pulmonary Medicine
• Surgical Oncology
• Transplant Surgery

Background:

• Medically refractory, lung-limited, stage IV non-small cell lung cancer (NSCLC) often leads to fatal respiratory failure.
• Lung transplantation is a potential curative option but has been historically limited by concerns over oncological outcomes.
• This study investigates the outcomes of lung transplantation in carefully selected NSCLC patients.

Purpose of the Study:

• To evaluate survival outcomes in patients with stage IV NSCLC who underwent lung transplantation.
• To compare survival rates between lung transplant recipients with NSCLC and those treated with medical management alone.
• To assess 1-year posttransplant survival in NSCLC patients compared to non-cancer patients undergoing lung transplant.

Main Methods:

• A prospective, single-center registry study included 404 adults.
• 17 patients with stage IV NSCLC underwent lung transplant; 81 received medical management.
• Contemporary staging and a dissemination-minimizing operative technique were employed.

Main Results:

• The 1-year overall survival for NSCLC patients who received a lung transplant was 100%, compared to 40.8% for those receiving medical management alone.
• 1-year posttransplant survival was 100% for NSCLC patients and 88.1% for non-cancer patients.
• At extended follow-up, only 2 of the 17 NSCLC transplant recipients had died.

Conclusions:

• Lung transplantation demonstrates favorable early survival in selected patients with medically refractory, lung-limited, stage IV NSCLC and respiratory failure.
• The findings suggest lung transplantation can be a viable option for this patient group.
• Further long-term follow-up and quality-of-life assessments are warranted.